Clinical Topics

Melanomas Associated With Internal Malignancy Risk

by U.S. Medicine

January 1, 2019

PALO ALTO, CA — Genetic and environmental risk factors have been associated with the development of multiple primary melanomas (MPM) but a new study questioned whether those patients might have increased predisposition to developing internal malignancies.

The report published in the Journal of the American Academy of Dermatology sought to identify the risk of subsequent malignancies in MPM patients.1

Researchers from the VA Palo Alto, CA, Health Care System and Stanford University Medical Center analyzed multiple primary standardized incidence ratios for patients with one or more, two or more and three or more primary melanomas (PM) in the SEER database from 1973-2014.

Ultimately, they identified 223,799 patients with one or more, 19,709 with two or more and 3,995 with three or more PM, and found that risks of subsequent internal malignancy increased with number of PM, with observed to expected (O/E) ratios of 0.99, 1.14, and 1.23 (p<0.05) for patients with at least one, two and three PM respectively.

The study team reported that Internal malignancy was higher in younger MPM patients and those with superficial spreading melanoma

Most frequent malignancies among MPM patients included breast, prostate, thyroid, soft tissue, brain, kidney, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia. Results indicated that risk of subsequent cutaneous melanoma increased with O/E ratios of 8.09, to 22.52, to 41.03 (p<0.05) respectively.

While limited by incomplete SEER information about pigmentation phenotypes, histology, and treatments, study authors concluded, “Patients with MPM have increased risk of subsequent internal and cutaneous malignancies and may benefit from tight adherence to age-specific cancer screening.”

1. Cai ED, Swetter SM, Sarin KY. Association of multiple primary melanomas with malignancy risk: a population-based analysis of the Surveillance, Epidemiology, and End Results Program database from 1973-2014. J Am Acad Dermatol. 2018 Oct 1. pii: S0190-9622(18)32637-9. doi: 10.1016/j.jaad.2018.09.027. [Epub ahead of print] PubMed PMID: 30287320.


Comments are closed here.


Related Articles

Effective Metrics Help VA Exceed National Goal for Colorectal Cancer Screening

More Than 80% of Patients Meet Recommendations LOS ANGELES—More than four out of five veterans eligible for colorectal cancer screening have been screened, putting the largest healthcare system in the United States among the top... View Article

More Options, Better Survival for Veterans With Metastatic Pancreatic Cancer

ALBANY, NY—Pancreatic cancer remains one of the deadliest malignancies in the United States, but new therapies can extend life and improve quality of life for many patients. That is especially the case at the VA,... View Article


U.S. Medicine Recommends


More From oncology

Oncology

Effective Metrics Help VA Exceed National Goal for Colorectal Cancer Screening

More Than 80% of Patients Meet Recommendations LOS ANGELES—More than four out of five veterans eligible for colorectal cancer screening have been screened, putting the largest healthcare system in the United States among the top... View Article

Oncology

More Options, Better Survival for Veterans With Metastatic Pancreatic Cancer

ALBANY, NY—Pancreatic cancer remains one of the deadliest malignancies in the United States, but new therapies can extend life and improve quality of life for many patients. That is especially the case at the VA,... View Article

Oncology

Military Risks for Ocular Surface Squamous Neoplasia

MIAMI—While a variety of risk factors have been evaluated in ocular surface squamous neoplasia, few studies have assessed risk factors specific to the armed forces veteran population. A report in the journal Eye and Vision... View Article

Oncology

Antibiotics Appear to Inhibit Tumor Activity in CTCL

AARHUS, DENMARK—Do CD4 T cell responses to  Staphylococcus aureus inadvertently enhance neoplastic progression in models of skin cancer and cutaneous T cell lymphoma? A prospective study in the journal Blood examined that question, exploring the... View Article

Oncology

Lower Dose Cisplatin Preferable in Squamous Cell Carcinoma

PHILADELPHIA—Chemoradiotherapy is commonly used for nonoperative treatment of locally advanced head and neck squamous cell carcinoma. The issue, according to a recent study, is that the standard dose of 100 mg/m2 cisplatin every three weeks is... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up